Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Michael Russoniello

Pulmonary Disease Denville, NJ Medical Doctor

NPI 1356392757 CMS profile 151789

16 Pocono Rd, Ste 209, Denville, NJ 07834

Open in the dashboard

General payments

$4,969

299 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michael Russoniello of Denville, NJ is reported in the CMS Open Payments database as having received $4,969 across 299 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $256 15
2023 General $1,516 83
2022 General $1,135 70
2021 General $823 48
2020 General $602 32
2019 General $637 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Russoniello
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Michael Russoniello were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Michael Russoniello Pulmonary Disease median Middle half National median
2019 $637 $377 $109–$1,340 $163
2020 $602 $230 $56–$907 $114
2021 $823 $269 $68–$1,072 $132
2022 $1,135 $390 $100–$1,457 $149
2023 $1,516 $419 $114–$1,659 $160
2024 $256 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $1,142 57 payments
  2. GlaxoSmithKline, LLC. $1,002 64 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $767 56 payments
  4. Mylan Specialty L.P. $277 15 payments
  5. Regeneron Healthcare Solutions, Inc. $214 11 payments
  6. Philips Electronics North America Corporation $207 12 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $149 9 payments
  8. Jazz Pharmaceuticals Inc. $110 8 payments
  9. Grifols USA, LLC $94 6 payments
  10. Covis Pharma B.V. $92 5 payments
  11. Other $915 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,951 298 payments
  2. Education $18 1 payment
Products named General payments · program years 2019–2024
  1. BREZTRI $676 24 payments
  2. TRELEGY ELLIPTA $613 38 payments
  3. FASENRA $398 19 payments
  4. SPIRIVA RESPIMAT $359 26 payments
  5. OFEV $324 24 payments
  6. AIRSUPRA $263 5 payments
  7. TEZSPIRE $261 5 payments
  8. SYMBICORT $256 5 payments
  9. YUPELRI $244 13 payments
  10. STIOLTO RESPIMAT $231 17 payments
  11. Other $2,670 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

501

Median for Internal Medicine: 777

Drug cost

$222,543

Median for Internal Medicine: $73,373

Branded share of claims

71.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 133 $156,821
Breo Ellipta Fluticasone/Vilanterol Brand 79 $41,501
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $7,280
Advair Hfa Fluticasone Propion/Salmeterol Brand 22 $5,797
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 26 $5,770
Albuterol Sulfate Hfa Albuterol Sulfate Brand 73 $2,656
Wixela Inhub Fluticasone Propion/Salmeterol Brand 12 $1,693
Prednisone Generic 88 $510
Omeprazole Generic 29 $373
Montelukast Sodium Generic 17 $76

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$60,540

Medicare's payments for the services billed

Medicare patients

239

Average age 76

Services billed

585

122 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 56%
Ischemic heart disease 53%
Arthritis 49%
Heart failure 44%
Diabetes 36%
Depression 36%
Atrial fibrillation 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $48
$48 — —
YUPELRI
  • Mylan Specialty L.P. $36
$36 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $33
$33 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $31
$31 — —
DUPIXENT
  • GENZYME CORPORATION $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

299 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record